Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epsolay
- Development stage
- Approved
- Lead developer
- Sol-Gel Technologies
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Epsolay is a topical cream containing 5% benzoyl peroxide encapsulated within silica-based microcapsules. Developed by Sol-Gel Technologies using its proprietary microencapsulation platform, the drug is designed to provide a controlled release of benzoyl peroxide to the skin. This delivery mechanism aims to maintain the drug's potent antimicrobial and anti-inflammatory efficacy while significantly reducing the skin irritation typically associated with high-concentration benzoyl peroxide. Epsolay was approved by the FDA in April 2022 for the treatment of inflammatory lesions of rosacea in adults and is commercialized in the United States by Galderma.
- Brand names
- Epsolay
- Other names
- encapsulated benzoyl peroxidebenzoyl peroxide 5% cream
Beyond the preview
Go deeper on Epsolay.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epsolay.